With increasing numbers of children and adults undergoing allogeneic haematopoietic stem cell transplantation (HSCT), neurotoxicity is emerging as an important cause of transplant-related morbidity.^[@bib1],\ [@bib2],\ [@bib3]^ The calcineurin inhibitor cyclosporine A (CI CSA) is the most frequently used agent for prevention of GvHD in both adult and paediatric patients. CSA is an established cause of post-transplantation central nervous system (CNS) toxicity, typically characterised by posterior reversible encephalopathy syndrome (PRES).^[@bib4]^ Even though neurological complications of CSA seldom result in mortality, the necessitated withdrawal of this potent anti-GvHD agent can have major implications on clinical outcome particularly in the face of on-going GvHD. The spectrum of CSA-related neurological complications has been well characterised in several case series of paediatric HSCT recipients,^[@bib5],\ [@bib6],\ [@bib7]^ however, long-term follow-up data of those children who experience neurotoxicity are lacking. Here, we present the outcome of 26 children who developed CSA-neurotoxicity following allogeneic HSCT.

From a cohort of 569 consecutive paediatric allogeneic HSCT recipients at our institution between 1 January 2003 and 31 December 2013, we retrospectively identified those children who developed neurological complications at any time after the start of conditioning whilst receiving CSA using a computerised search of our patient database. Children with clinical symptoms of PRES or neurological manifestations of thrombotic microangiopathy (TMA)^[@bib7]^ were included. Those with obvious alternate causes for neurotoxicity were excluded. All children who suffered CNS complications were clinically evaluated by a neurologist. Supplementary investigations such as computed tomography (CT) or magnetic resonance imaging (MRI) scan of head, cerebrospinal fluid analysis and electroencephalogram were used as appropriate to identify the cause. PRES was diagnosed in accordance with its well described MRI appearance.^[@bib8]^ Hypodense lesions in the parieto-occipital areas were considered to be CT findings consistent with PRES. TMA was diagnosed based on clinical and laboratory features of microangiopathic haemolytic anaemia and thrombocytopenia. GvHD was diagnosed clinically and supported with histological confirmation where possible.^[@bib9]^ IV CSA administration at a dose of 5 mg/kg/day in two divided doses was commenced either on day −1 (2003--2008) or day −3 (2009 onwards). Levels were monitored twice weekly. Target trough serum levels were 100--150 ng/mL for HLA-identical sibling transplants and 150--200 ng/mL for unrelated donor transplants.

During the 11-year study period, 569 paediatric allogeneic HSCTs were performed at this centre. Twenty-six children developed neurotoxicity associated with CSA (4.6%). Their demographics, disease characteristics and transplant-related parameters are summarised in [Table 1](#tbl1){ref-type="table"}. Median age at HSCT was 8.3 years (range 0.5--12.8 years). CSA+MMF was the most commonly employed GvHD prophylaxis (*n*=19), followed by CSA+MTX (*n*=4) and CSA alone (*n*=3). In one patient (subject \#19), CSA was changed to Tacrolimus because of renal toxicity before the development of neurotoxicity that is, in this patient neurotoxicity occurred while being treated with Tacrolimus. Twenty-one children experienced CI-related neurotoxicity during their primary transplant procedure and 5 children following their second HSCT, having tolerated CSA without adverse events during their first HSCT.

Median time from HSCT to neurotoxicity was 47.5 days (range day --1 to +545) ([Table 1](#tbl1){ref-type="table"}). Clinical symptoms of neurotoxicity and severity are listed in [Table 1](#tbl1){ref-type="table"}. Twenty-four out of 26 patients had radiological evaluation of the brain with MRI, CT or both; 19 had classical findings of PRES, 2 showed non-specific changes consistent with encephalopathy and 3 had normal appearances of the brain. CSA level in peripheral blood at the time of presentation with neurotoxicity ranged from 64 to 256 ng/mL ([Table 1](#tbl1){ref-type="table"}).

Management of CI-induced neurotoxicity in addition to supportive care consisted of discontinuation of CSA/Tacrolimus in 25/26 patients. Neurological symptoms fully resolved in all patients except in patient \#9 who developed TMA and died shortly thereafter and patient \#3 who continues to require anticonvulsants despite normalisation MRI appearance. One patient (\#12) who presented with seizures on day +24 and had non-specific features on MRI with a normal EEG was continued on IV CSA along with anticonvulsants and had no further neurological events.

After a median of 11 days post onset of CSA neurotoxicity (range 0--597 days) a CI was reintroduced in 18 patients: in 10 patients CSA was used and in 12 patients Tacrolimus, 3 of whom had failed re-challenge with CSA ([Table 2](#tbl2){ref-type="table"}). One patient received Tacrolimus after having been successfully re-challenged with CSA (patient \#25). Eight of 18 patients re-challenged with a CI had recurrent symptoms of neurotoxicity: 3 following re-challenge with CSA, 2 following re-challenge with Tacrolimus and 3 following re-challenge with CSA as well as Tacrolimus sequentially. In addition to attempted re-challenge with a CI, all but one patient with grade I skin GvHD only before the onset of neurotoxicity, received corticosteroids as GvHD prophylaxis/treatment. Other immunosuppressive agents used are listed in [Table 2](#tbl2){ref-type="table"}.

Despite these measures, 7/9 patients (78%) who had no prior GvHD, developed acute/late acute GvHD after onset of CSA neurotoxicity whereas 13/17 had recurrence, persistence or progression of acute/late acute GvHD. Twenty-three patients were evaluable for chronic GvHD as 2 died before day +100 and one patient had second HSCT before day +100. Eighteen out of 23 (78%) had chronic GvHD and this was extensive in 14 patients: 13 patients developed chronic GvHD following CSA-neurotoxicity whereas pre-existing chronic GvHD persisted or progressed in 5 patients ([Table 2](#tbl2){ref-type="table"}).

At a median of 176 days (range 7--1889 days) following development of CSA-induced neurotoxicity 15/26 (58%) patients died, most due to progressive GvHD or its complications ([Table 2](#tbl2){ref-type="table"}). There were no acute deaths from neurotoxicity except in one patient (subject \#9) who had CSA-related TMA on day +61 and died of encephalopathy and respiratory failure on day +68. Currently, 11/26 (42%) of children are alive a median of 8.2 years (range 5.5--13.1 years) after HSCT and a median of 7.8 years (range 5.5--12.1 years) after development of CSA-neurotoxicity. In contrast, during the same study period in our institution, the overall survival at 5 years following allogeneic HSCT was 67.7% for haematological malignancy, 82.1% for immunodeficiency and 87.2% for metabolic disorders. Of the 11 children who survived despite developing CSA-related neurotoxicity, 4 (36%) have a significantly impaired quality-of-life due to sequelae of extensive chronic GvHD.

This case series of paediatric HSCT recipients who developed CSA-related neurotoxicity illustrates that outcome following this complication is notably poor: high non-relapse mortality of 58% and significant morbidity with 36% of survivors living with late effects of extensive chronic GvHD. These findings are similar to those in large case series of adult allogeneic HSCT recipients who developed CSA-related neurotoxicity reporting 43--52% mortality due to progressive GvHD/infection.^[@bib10],\ [@bib11]^ In our study, outcome was particularly poor in the 10 patients who had severe GvHD (Grade III/IV) before the development of CSA-neurotoxicity: 8/10 died and 2 are alive with extensive vitiligo. In the same time period at our institution, other patients with severe GvHD, but without the added complication of CSA neurotoxicity had a far superior survival rate of 70%.^[@bib12]^ Hence it would seem that the development of CSA neurotoxicity and consequent inability to tolerate CI, adversely affected their prognosis. In future studies with larger patient numbers, it would be useful to substantiate our findings with multivariate analyses.

Development of CSA-related neurotoxicity poses a complex clinical management situation as one of the most effective drugs in the treatment and prevention of GvHD needs to be discontinued promptly; sometimes in patients with on-going GvHD. As symptoms of CSA-neurotoxicity usually resolve over several days, re-challenge could be a viable option. Tacrolimus has been used as alternative agent in the event of CSA-related neurotoxicity but as it is also a CI, its use is similarly associated with significant neurotoxicity ^[@bib7],\ [@bib13],\ [@bib14]^ as seen in 5 patients in our case series. Nevertheless, re-challenge with a CI was tolerated in 56% of patients in this series, a similar proportion as that reported by others.^[@bib10]^ In those patients where re-challenge resulted in recurrence of symptoms and use of CI was precluded permanently, outcome appears particularly dismal with overall survival of 13% (1/8) in this case series.

Evidence for the optimal approach of prophylaxis/management of GvHD when use of CI is contra-indicated is not available. In this case series, all but one patient received corticosteroids. In addition, as the combination of CSA and MMF is the most common GvHD prophylaxis regimen in our centre, the majority of patients were already receiving MMF at the time of development of CSA neurotoxicity. The efficacy of MMF as sole anti-GvHD agent is limited,^[@bib13]^ and on its own it does not provide satisfactory GvHD prophylaxis or treatment. Sirolimus, which has a completely different mechanism of action to the CI provides another option. Although Sirolimus can also cause neurotoxicity, this has mostly been reported when it has been used in combination with CSA.^[@bib15]^ In this series, Sirolimus was only used in five patients but this agent may potentially be increasingly used in this clinical situation in future.

In conclusion, this case series illustrates the dismal prognosis in patients following the development of CI-related neurotoxicity and the complexities of managing GvHD in this situation. There is a need for further studies to determine the optimal treatment approach to improve outcome following this rare but serious complication.
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###### Patient characteristics

  *Patient no.*    *Sex/age at HSCT (years)*         *Diagnosis*                     *Donor*               *Cell source*    *Conditioning regimen*     *GvHD prophylaxis*   *Day CSA neurotoxicity*   *CSA level at time Neurotoxicity (μg/L)*   *Presentation of neurotoxicity (grading)[a](#t1-fn2){ref-type="fn"}*           *Description of neurotoxicity/ associated symptoms*
  --------------- --------------------------- ------------------------- --------------------------------- --------------- --------------------------- -------------------- ------------------------- ------------------------------------------ ---------------------------------------------------------------------- ---------------------------------------------------------------------
  1                           M/9                      Ph+ ALL                       MUD^b^                    PBSC                 Flu/TBI                 CSA/MMF                   248                               248                                                 PRES (grade 3)                                                           Seizures
  2                          M/10                        MDS             MUD[b](#t1-fn3){ref-type="fn"}         BM             Flu/Cyclo/Campath              CSA                     363                               147                                                 PRES (grade 3)                                  Transient blindness, tremors, severe hypertension, seizures
  3                           M/4                        MDS                           MUD                     PBSC             Flu/Mel/Campath             CSA/MMF                   60                                239                                                 PRES (grade 3)                                                  Status epilepticus, tremors
  4                           F/8                   Relapsed ALL                       MSD                      BM                 Cyclo/TBI                  CSA                     30                                256                                                 PRES (grade 4)                                              Hypertension, reduced consciousness
  5                           F/8                      Ph+ ALL                         MSD                      BM                 Cyclo/TBI                  CSA                      1                                 89                                                 PRES (grade 3)                                                 Hypertension, syncopal attack
  6                           M/5                        AML                          MMUD                     Cord              Bu/Cyclo/Mel               CSA/MMF                   16                                186                                                 PRES (grade 3)                                               Hypertension, headaches, seizure
  7                           M/6                  MDS monosomy 7                      MSD                      BM               Bu/Cyclo/Mel               CSA/MTX                   −1                   ND[c](#t1-fn4){ref-type="fn"}                                    PRES (grade 4)                                                            Seizure
  8                          M/11                       T-NHL                         MMUD                     PBSC            Cyclo/TBI/Campath            CSA/MMF                   115                               124                                                 PRES (grade 3)                                                Seizures, tremors, hypertension
  9                          M/11                   Relapsed AML                       MSD                      BM               Bu/Cyclo/Mel               CSA/MTX                   61                                161                                                 TMA (grade 3)                               Seizures, hypertension, encephalopathy, cytopenia, renal impairment
  10                          M/5                     JMML-AML                        MMUD                     Cord                Flu/Treo                 CSA/MMF                   28                                137                                                 PRES (grade 3)                                       Headache, encephalopathy, seizures, hypertension
  11                         M/12                        AML                          MMUD                      BM           Bu/Cyclo/Mel/Campath           CSA/MMF                   181                               201                                                 PRES (grade 4)                                           Seizure, hypertension, visual impairment
  12                         M/11                        XLP                          MMUD                     PBSC             Flu/Mel/Campath             CSA/MMF                   24                                100                                                 PRES (grade 3)                                                     Seizure, hypertension
  13                          M/7                        XLP             MMUD[b](#t1-fn2){ref-type="fn"}       PBSC             Flu/Mel/Campath             CSA/MMF                   202                               154                                                 PRES (grade 3)                                                     Seizure, hypertension
  14                          M/5                        HLH                          MMUD                     Cord               Cyclo/Treo                CSA/MMF                   34                                106                                                 PRES (grade 4)                                                    Seizures, hypertension
  15                         F/0.5                       HLH                          MMUD                     Cord                Flu/Treo                 CSA/MMF                   232                               103                                                 PRES (grade 2)                                                    Seizures, hypertension
  16                          M/2                       SCID                           MUD                      BM              Flu/Mel/Campath             CSA/MMF                   77                                 64                                                 PRES (grade 2)                                                    Seizures, hypertension
  17                         F/0.5                      SCID                           MUD                     Cord                Flu/Treo                 CSA/MMF                   15                                142                                                 TMA (grade 3)                                            Headache, hypertension, renal impairment
  18                          F/7                        CID                          MMUD                     PBSC             Flu/Mel/Campath             CSA/MMF                   93                                 84                                                 PRES (grade 3)                                                            Seizure
  19                         M/10                        CGD                           MUD                     PBSC            Flu/Treo/Campath        CSA/MMF\> TAC/MMF              545                                UN                                                 PRES (grade 2)                                                  Seizures, renal impairment
  20                         F/10                Schwachmann diamond                   MUD                     PBSC             Flu/Mel/Campath             CSA/MMF                   165                               109                                                 PRES (grade 3)                                                    Seizures, hypertension
  21                         F/10                 Aplastic anaemia                     MSD                    BM+cord                Cyclo                  CSA/MTX                    0                                151                                                 PRES (grade 4)                                            Seizures, hypertension, encephalopathy
  22                         M/10              Beta thalassaemia major               MSD^b^                    PBSC                   Mel                   CSA/MMF                   169                               193                                                 PRES (grade 4)                                                   Seizures, encephalopathy
  23                          F/4                   Osteopetrosis                      MSD                      BM                  Bu/Flu                  CSA/MMF                   16                                 57                                                 PRES (grade 2)                                                           Seizures
  24                          F/3                   Osteopetrosis                      MUD                     PBSC        Flu/Treo/Campath/Thiotepa        CSA/MMF                   13                                175                                                 PRES (grade 4)                                               Seizures, hypertension, headache
  25                         F/10                   Systemic JIA                     MMUD^b^                   PBSC             Flu/Mel/Campath             CSA/MMF                   35                                155                                                 PRES (grade 3)                                                   Seizures, encephalopathy
  26                          M/8               Adrenoleukodystrophy                   MUD                      BM             Bu/Cyclo/Campath             CSA/MTX                    4                                 83                                                 PRES (grade 2)                                                      Headaches, seizures

Abbreviations: ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukemia; BM=bone marrow; Bu=busulphan; CGD=chronic granulomatous disease; CID=combined immunodeficiency; CSA=cyclosporine; Cyclo=cyclophosphamide; HLH=haemophagocytic lymphohistiocytosis; JIA=juvenile idiopathic arthritis; MDS=myelodysplastic syndrome; Mel=melphalan; MMF=mycophenolate mofetil; MSD=matched sibling donor; MMUD=mismatched unrelated donor; MUD=mismatched unrelated donor; MTX=methotrexate; ND=not done; T-NHL=T-cell non-Hodgkin lymphoma; Treo=treosulphan; UN=unknown; XLP=X-linked lymphoproliferative disease.

As per Common Terminology Criteria for Adverse Events.

Second HSCT.

This patient developed PRES on the day of starting CSA.

###### Immunosuppression, GvHD and outcome following CSA-related neurotoxicity

  *Patient no.*           *Immune suppression post CSA toxicity*           *Interval before re-starting CSA/TAC*         *Maximum GvHD pre CSA toxicity acute and chronic*            *Evolution of GvHD post CSA neurotoxicity*     *Outcome/follow-up*[a](#t2-fn2){ref-type="fn"} *cause death/current complications*                        
  --------------- ------------------------------------------------------- --------------------------------------- ---------------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------------ --------------------- ------------------------------------------------------------------------------------
  1                       TAC[b](#t2-fn3){ref-type="fn"}, CS, mAb                           219                             Grade II skin, extensive chronic skin, mouth                                 Nil                                            Progressed to extensive skin, mouth and lung                       Alive +7.8 years                             Extensive bronchiolitis obliterans
  2                                       CS, MMF                                           NA                                              Grade I skin                                     Progressed to Grade II skin                                           Developed limited skin                                  Alive +12.1 years                                      GvHD resolved
  3                                  CSA/TAC^^c^^, CS                                       20                                         Grade IV skin and gut                                 Grade IV skin, gut recurred                                          Developed extensive skin                                 Alive +10.3 years    Extensive vitiligo, epilepsy following PRES needing treatment with anti-epileptics
  4                                         Nil                                             NA                                              Grade I skin                                        Grade I skin recurred                                                       Nil                                            Alive +8.1 years                                              
  5                                       TAC, CS                                           132                                                 Nil                                        Developed Grade III skin, liver                                     Developed extensive skin, lung                              Alive +5.9 years             Bronchiolitis obliterans, bilateral avascular necrosis of the hip
  6                            TAC, CS, MMF, Siro, mAb, MSC                                 597                                          Grade IV skin, gut                                  Grade IV skin, gut persisted                                      Developed limited skin, liver                              Deceased +1.8 years                                       Liver GvHD
  7                    TAC[c](#t2-fn4){ref-type="fn"}, CS, MMF, mAb                         228                                                 Nil                                          Developed Grade IV skin, gut                                   Developed extensive skin, gut, liver                          Deceased +293 days                            Bronchiolitis obliterans/infection
  8                CSA/TAC[c](#t2-fn4){ref-type="fn"}, CS, MMF, MTX, mAb                     2                             Grade IV skin, gut, extensive chronic skin/gut                                Nil                                              Progressed to extensive skin, gut, liver                        Deceased +1.2 years              GvHD, infection (*E. coli* sepsis, pulmonary Aspergillosis)
  9                                       TAC, CS                                            0                                       Grade IV skin, gut, liver                           Grade IV skin, gut, liver persisted                                                 NE                                            Deceased +68 days                                      Infection, TMA
  10                                      CS, MMF                                           NA                                                  Nil                                             Developed Grade II gut                                             Developed limited gut                                  Deceased +1.6 years                        Acute liver necrosis, presumed infection
  11                   CSA[c](#t2-fn4){ref-type="fn"}, CS, MMF, Siro                         3                                             Grade II skin                                     Progressed to Grade III skin                                      NE[d](#t2-fn5){ref-type="fn"}                              Deceased +275 days           Bone marrow aplasia, fungal chest infection, CMV/adeno/HHV6 viraemia
  12                      CSA[e](#t2-fn6){ref-type="fn"}, CS, MMF                           10                                                  Nil                                            Developed Grade II skin                                             Developed limited skin                                  Alive +10.4 years                                      GvHD resolved
  13                                   CS, MMF, mAb                                         NA                                  Grade II skin, limited chronic skin                           Progressed to Grade IV gut                              Limited skin persisted. Developed extensive gut                      Alive +7.8 years                                       GvHD resolved
  14                                CS, Siro, mAb, MSC                                      NA                                         Grade IV skin and gut                                    Grade IV gut persisted                                            Developed extensive gut                                  Alive +6.2 years                                       GvHD resolved
  15                                      TAC, CS                                           30                                              Grade 1 skin                                   Progressed to Grade IV skin, gut                                    Developed extensive skin, gut                              Deceased +298 days                            GvHD, infection (RSV pneumonitis)
  16                 CSA/TAC[c](#t2-fn4){ref-type="fn"}, CS, mAb, MSC                        4                                          Grade III skin, gut                            Progressed to Grade IV skin, gut, liver                              Developed extensive skin, gut, liver                          Deceased +253 days                                      GvHD/infection
  17                            CSA, CS, MMF, mAb, ATG, MSC                                  1                                             Grade IV skin                            Grade IV skin persisted Developed Grade IV gut                                           NE                                            Deceased +66 days                               GvHD, pulmonary haemorrhage
  18                                   CS, MMF, mAb                                         NA                                              Grade I gut                                   Progressed to Grade III skin, gut                                    Developed extensive skin, gut                              Deceased +1.9 years                                          GvHD
  19                   TAC[c](#t2-fn4){ref-type="fn"}, CS, MMF, mAb                          0                     Grade III skin, gut, liver, extensive chronic skin, gut, liver                        Nil                                                extensive skin, gut, liver persisted                          Deceased +1.9 years                           Infection (Influenza pneumonitis)
  20                   CSA[c](#t2-fn4){ref-type="fn"}, CS, Siro mAb                         12                            Grade III skin, gut, extensive chronic skin, gut                   Grade III skin, gut recurred                                 Progressed to extensive skin, gut, liver                        Deceased +304 days                             GvHD, infection (adenoviraemia)
  21                        CSA[c](#t2-fn4){ref-type="fn"}, CS                               4                                                  Nil                                                      Nil                                                                Nil                                           Deceased +5.2 years                                   Pulmonary fibrosis
  22                                   TAC, CS, MMF                                         343                                          Grade IV skin, gut                                              Nil                                                   Developed extensive skin, gut                               Alive +10.3 years                                    Extensive vitiligo
  23                                      CS, MMF                                           NA                                                  Nil                                             Developed Grade I skin                                                      Nil                                            Alive +5.5 years                                       GvHD resolved
  24                                   CS, MMF, Siro                                        NA                                                  Nil                                                      Nil                                                                Nil                                           Deceased +125 days                            Pulmonary vasculopathy, infection
  25                               CSA/TAC, CS, MMF, mAb                                     5                                                  Nil                                          Developed Grade IV skin, gut                                      Developed extensive gut, liver                             Deceased +1.6 years                                       Infection
  26                                      CSA, CS                                           20                                                  Nil                                             Developed Grade I skin                                                      Nil                                            Alive +7.9 years                                       GvHD resolved

Abbreviations: CS=corticosteroids; CSA=cyclosporine; mAb=monoclonal antibodies including infliximab, daclizumab and/or basiliximab; MMF=mycophenolate mofetil; MSC=mesenchymal stem cells; MTX=methotrexate; NA=not applicable; NE=not evaluable; RSV=respiratory syncytial virus; Siro=sirolimus; TAC=Tacrolimus.

As of 1 April 2016 except for patient \#22 for whom last follow-up was 27 September 2012.

Tacrolimus started to assess if tolerated in context of potential lung transplantation.

CSA and/or Tacrolimus restarted but not tolerated.

NE as received second HSCT.

CSA continued with clobazam.
